Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 146-152

  Greenwood Van Meerveld, Beverley ^a,b   Mohammadi, Ehsan ^b   Tyler, Karl ^b   Pietra, Claudio ^c   Bee, Lucy A ^d   Dickenson, Anthony ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c HELSINN HEALTHCARE SA   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; NETUPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; PALONOSETRON; SEROTONIN 3 ANTAGONIST; DRUG COMBINATION; ISOQUINOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 RECEPTOR;

ABDOMINAL WALL MUSCULATURE; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON DILATATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EVOKED RESPONSE; IRRITABLE COLON; MALE; MECHANICAL STIMULATION; MUSCLE CONTRACTION; NERVE CELL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHIC PAIN; NONHUMAN; RAT; SPINAL CORD DORSAL HORN; THERMAL STIMULATION; VISCERAL PAIN; VON FREY TEST; ACTION POTENTIAL; ANIMAL; COLON; DRUG COMBINATION; DRUG EFFECTS; INNERVATION; METABOLISM; NOCICEPTIVE PAIN; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; POSTERIOR HORN CELL; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; COLON; DRUG COMBINATIONS; DRUG SYNERGISM; ISOQUINOLINES; MALE; NEUROKININ-1 RECEPTOR ANTAGONISTS; NOCICEPTIVE PAIN; POSTERIOR HORN CELLS; PYRIDINES; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VISCERAL PAIN;

EID: 84907177312     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216028     Document Type: Article

References (36)

1. Chang L (2005) Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder? Gastroenterol Clin North Am 34: 271-279.
2. Coates MD, Johnson AC, Greenwood-Van Meerveld B, and Mawe GM (2006) Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 18:464-471.
3. Gaudreau GA and Plourde V (2003) Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat. Neurosci Lett 351:59-62.
4. Gilron I, Jensen TS, and Dickenson AH (2013) Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol 12:1084-1095.
5. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, and Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577.
6. Green GM, Scarth J, and Dickenson A (2000) An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT(3) receptors in the anaesthetized rat. Pain 89:81-88.
7. Greenwood-Van Meerveld B, Gibson MS, Johnson AC, Venkova K, and Sutkowski- Markmann D (2003) NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav 74:1005-1013.
8. Hayashida K, Kimura M, Yoshizumi M, Hobo S, Obata H, and Eisenach JC (2012) Ondansetron reverses antihypersensitivity from clonidine in rats after peripheral nerve injury: role of g-aminobutyric acid in a2-adrenoceptor and 5-HT3 serotonin receptor analgesia. Anesthesiology 117:389-398.
9. Ho KY and Gan TJ (2006) Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 19:606-611.
10. Hoffmann-Emery F, Hilpert H, Scalone M, and Waldmeier P (2006) Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives. J Org Chem 71:2000-2008.
11. Hu WP, You XH, Guan BC, Ru LQ, Chen JG, and Li ZW (2004) Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett 365:147-152.
12. Kim SH and Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
13. Minami M, Endo T, Yokota H, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yoshioka M, Nagahisa A, and Andrews PL (2001) Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 428:215-220.
14. Ness TJ and Gebhart GF (1988) Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res 450:153-169.
15. Parenti C, Aricò G, Ronsisvalle G, and Scoto GM (2012) Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain. Peptides 34:412-418.
16. Pietra C, Tyler KR, Weaver VA, Mohammadi E, and Greenwood-Van Meerveld B (2012) Decreased visceral sensitivity produced by a combination of the 5-HT3 receptor antagonist palonosetron and of the NK1 receptor antagonist netupitant in a rodent model of visceral hypersensitivity (Abstract Mo1651). Gastroenterology 142 (Suppl 1): S650.
17. Plourde V, St-Pierre S, and Quirion R (1997) Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Am J Physiol 273: G191-G196.
18. Poitras P, Riberdy Poitras M, Plourde V, Boivin M, and Verrier P (2002) Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 47: 914-920.
19. 1receptor selective antagonist Netupitant. Peptides 37:86-97.
20. Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, and Slusher BS (2010b) The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335:362-368.
21. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, and Snyder SH, et al. (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469-478.
22. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, and Slusher BS (2010a) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193-199.
23. Rubenstein EB (2004) Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2:284-289.
24. Siddiqui MA and Scott LJ (2004) Palonosetron. Drugs 64:1125-1132, discussion 1133-1134.
25. Sikandar S, Ronga I, Iannetti GD, and Dickenson AH (2013) Neural coding of nociceptive stimuli-from rat spinal neurones to human perception. Pain 154:1263-1273.
26. Stacher G (2002) Palonosetron (Helsinn). Curr Opin Investig Drugs 3:1502-1507.
27. Stathis M, Pietra C, Rojas C, and Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689:25-30.
28. Suzuki R, Hunt SP, and Dickenson AH (2003) The coding of noxious mechanical and thermal stimuli of deep dorsal horn neurones is attenuated in NK1 knockout mice. Neuropharmacology 45:1093-1100.
29. Suzuki R, Morcuende S, Webber M, Hunt SP, and Dickenson AH (2002) Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 5:1319-1326.
30. Suzuki R, Rahman W, Hunt SP, and Dickenson AH (2004) Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res 1019:68-76.
31. Thomas AG, Rojas C, and Slusher BS (2014) NK1 receptor internalization and protein kinase C activation by netupitant and palonosetron in NG108-15 cells. Exp Brain Res, in press.
32. Venkova K and Greenwood-Van Meerveld B (2004) Effects of TAK-637 on NK(1) receptor-mediated mechanisms regulating colonic secretion. Toxicol Appl Pharmacol 196:215-222.
33. Venkova K, Sutkowski-Markmann DM, and Greenwood-Van Meerveld B (2002) Peripheral activity of a new NK1 receptor antagonist TAK-637 in the gastrointestinal tract. J Pharmacol Exp Ther 300:1046-1052.
34. Wang Y, Mu X, Liu Y, Zhang X, Wu A, and Yue Y (2011) NK-1-receptor-mediated lesion of spinal post-synaptic dorsal column neurons might improve intractable visceral pain of cancer origin. Med Hypotheses 76:102-104.
35. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, and Schuster MM (1990) Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 98:1187-1192.
36. Zhou Q, Fillingim RB, Riley JL, 3rd, Malarkey WB, and Verne GN (2010) Central and peripheral hypersensitivity in the irritable bowel syndrome. Pain 148:454-461.